$38.28 1.05 (2.82%)
15:54 EST PFE Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 223.92B
PE Ratio 10.63
Volume (Avg. Vol.) 47.37M
Day's Range 37.60 - 38.80
52-Week Range 27.88 - 41.99
Dividend & Yield 1.36 (3.55%)
PFE Stock Predictions, Articles, and Pfizer News
- From InvestorPlace
- From the Web
Buying stocks that have been hit by a serious but solvable problem, can lead to extraordinary gains when things work out positively.
The company is a proven winner but Pfizer stock won't win any awards for excitement. Long-term investors can reap strong dividend rewards; short-term movement is murkier.
Vaccine news thrust Pfizer center stage this month. But it's PFE stock's beefy dividend that's the real story.
Pfizer looks like good value with its vaccine catalyst and dividend yield. PFE stock will be 60% higher within several years after the FDA grants EUA for its Covid-19 vaccine.
The Dow just crossed 30,000 for the first time ever. Dive in to learn more about the three reasons behind this record move.
Simply put, blockchain is the safest way to store and transfer information ever created, which makes it ideal for tracking vaccines.
With a new Covid vaccine update today, how do the Moderna and Pfizer coronavirus vaccines compare? Dive in here.
Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives. With them, we can solve Covid-19.
We’re heading into the seasonally strong time of year, and as Thanksgiving week approaches, it is likely the market will take off. So, if you have any cash to invest, please be invested before Thanksgiving!
By Ian Cooper
After the volatility of 2020, analysts see some calm in the offing. Here are 5 companies to invest in on those prospects.
While Matt McCall hopes some of your stocks were up big today, he also suggests keeping an even keel. Here are his three key takeaways to today's market action.
Pfizer stock is rallying higher Monday on coronavirus vaccine results, and it's taking the rest of the stock market with it.
Take a look at four value stocks from sectors that have underperformed lately. In addition to valuations, these stocks have robust dividend yield.
If you’re interested in high-growth biotech stocks with superior fundamentals, here are which ones to consider, and which ones to skip.
By Ian Cooper
While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Avoid INO stock for now.
Here are top stocks to buy that have a robust dividend pay-out in addition to being relatively low beta stocks. Simply put, these are dividend value creators.
Pfizer, Peloton, Fastly and Spartan Energy Acquisition were our top stock trades for Monday. Let's take a look at the charts.
Navellier RatingsPowered by Portfolio Grader